Pharma titans merge consumer health businesses

19 December 2018

British drug major GlaxoSmithKline (LSE: GSK) and US giant Pfizer (NYSE: PFE) this morning announced their intention to combine their consumer health businesses into a new world-leading joint venture, with combined sales of approximately £9.8 billion ($12.7 billion).

GSK will have a majority controlling equity interest of 68% and Pfizer will have an equity interest of 32% in the JV, and lays the foundation for the separation of GSK to create two new UK-based global companies focused on pharmaceuticals and vaccines and consumer healthcare. GSK’s shares jumped 7.29% to 1,553.80 pence soon after markets opened this morning.

GSK has already significantly expanded it consumer arm, buying out Switzerland-based Novartis’ (NOVN: VX) share in a consumer JV earlier this year for $13 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK